Clinical Trial

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase II single-arm study designed to evaluate the efficacy and safety of cryoablation combined with tislelizumab and platinum-based doublet chemotherapy as neoadjuvant therapy, followed by adjuvant tislelizumab therapy in patients with resectable stage II-IIIB non-small cell lung cancer (NSCLC). The study consists of a screening phase, a treatment phase (including the neoadjuvant stage, surgery, and adjuvant stage), a safety follow-up period, and a survival follow-up period.
Trial Details
NCT Number NCT06939127
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 38 participants
Start Date 2025-04-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-22